Drugs related to monoamine oxidase activity
暂无分享,去创建一个
[1] P. Gareri,et al. Conventional and new antidepressant drugs in the elderly , 2000, Progress in Neurobiology.
[2] S. Dimauro,et al. Therapeutic prospects for mitochondrial disease. , 2010, Trends in molecular medicine.
[3] Z. Fišar. Pathophysiology of Mood Disorders and Mechanisms of Action of Antidepressants and Mood Stabilizers , 2013 .
[4] Alessandro Serretti,et al. Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research , 2013, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[5] R. Malenka,et al. Synaptic Plasticity: Multiple Forms, Functions, and Mechanisms , 2008, Neuropsychopharmacology.
[6] C. Robert Cloninger,et al. Association of monoamine oxidase (MAO) activity with alcoholism and alcoholic subtypes. , 1993, American journal of medical genetics.
[7] W Poewe,et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease , 2006, European journal of neurology.
[8] Z. Fišar,et al. Neurotransmission in Mood Disorders , 2012 .
[9] R. Maj,et al. Safinamide , 2006, Neurology.
[10] L. Siever,et al. Biological Markers for Schizophrenia and the Biological High‐Risk Approach , 1985, The Journal of nervous and mental disease.
[11] C. Andrade,et al. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications , 2010, Mens Sana Monographs.
[12] M. Beal,et al. Mitochondrial diseases of the brain. , 2013, Free radical biology & medicine.
[13] X. Ou,et al. Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[14] M. Youdim,et al. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression , 2002, Psychopharmacology.
[15] A. Andreazza,et al. An updated meta-analysis of oxidative stress markers in bipolar disorder , 2014, Psychiatry Research.
[16] M. Mattson,et al. Mitochondria in Neuroplasticity and Neurological Disorders , 2008, Neuron.
[17] David S. Miller,et al. Neuropsychiatric symptoms in Alzheimer’s disease , 2011, Alzheimer's & Dementia.
[18] K. Lim,et al. Parkin Regulation and Neurodegenerative Disorders , 2016, Front. Aging Neurosci..
[19] Dennis S. Charney,et al. Neurobiological mechanisms in major depressive disorder , 2009, Canadian Medical Association Journal.
[20] Yun-Fai Chris Lau,et al. Regulation of monoamine oxidase A by the SRY gene on the Y chromosome , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] T. Morrison,et al. The role of serotonin, vasopressin, and serotonin/vasopressin interactions in aggressive behavior. , 2014, Current topics in behavioral neurosciences.
[22] J. V. van Amsterdam,et al. Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction. , 2006, Life sciences.
[23] Xingshu Li,et al. Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease. , 2012, Journal of medicinal chemistry.
[24] P. Gillman,et al. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction , 2007, British journal of pharmacology.
[25] M. Youdim,et al. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness , 2006, British journal of pharmacology.
[26] Irene Bolea,et al. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. , 2011, Journal of medicinal chemistry.
[27] M. Naoi,et al. Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. , 2012, Current topics in medicinal chemistry.
[28] Hayley M. Dorfman,et al. Neurobiological mechanisms for impulsive-aggression: the role of MAOA. , 2014, Current topics in behavioral neurosciences.
[29] M. Bourin,et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder , 2007, Acta psychiatrica Scandinavica. Supplementum.
[30] Wayne C. Drevets,et al. Neuroreceptor imaging in depression , 2013, Neurobiology of Disease.
[31] Tadafumi Kato,et al. Mitochondrial Dysfunction as the Molecular Basis of Bipolar Disorder , 2007, CNS Drugs.
[32] F. Stocchi,et al. Rasagiline for the treatment of Parkinson’s disease: an update , 2015, Expert opinion on pharmacotherapy.
[33] M. Weinstock,et al. Ladostigil prevents age-related glial activation and spatial memory deficits in rats , 2011, Neurobiology of Aging.
[34] V. Marzo,et al. Endocannabinoid control of food intake and energy balance , 2005, Nature Neuroscience.
[35] M. Youdim,et al. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor , 2003, Neuroscience Letters.
[36] M. Liebowitz,et al. Pharmacological treatment of social anxiety disorder: A meta‐analysis , 2003, Depression and anxiety.
[37] M. Sawada,et al. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. , 2006, Journal of neural transmission. Supplementum.
[38] H. Möller,et al. Recent progress in pharmacological and non-pharmacological treatment options of major depression. , 2006, Current pharmaceutical design.
[39] N. Akula,et al. Genetic Variation in Cholinergic-Muscarinic-2 Receptor Gene Modulates Muscarinic2-Receptor Binding In Vivo and Accounts for Reduced Binding in Bipolar Disorder , 2010, Molecular Psychiatry.
[40] A. Schrag,et al. Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson’s Disease , 2008, CNS drugs.
[41] B. Gutiérrez,et al. High‐activity variants of the uMAOA polymorphism increase the risk for depression in a large primary care sample , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[42] B. Devlin,et al. Haplotypes of the monoamine oxidase genes and the risk for substance use disorders , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[43] W. Burkard,et al. Biochemistry and pharmacology of moclobemide, a prototype RIMA , 2005, Psychopharmacology.
[44] M. Weinstock,et al. Ladostigil prevents gliosis, oxidative–nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats , 2007, Neuropharmacology.
[45] A. Takahashi,et al. Neurogenetics of aggressive behavior: studies in rodents. , 2014, Current topics in behavioral neurosciences.
[46] A. Serretti,et al. The genetics of bipolar disorder: genome ‘hot regions,’ genes, new potential candidates and future directions , 2008, Molecular Psychiatry.
[47] S. Stahl,et al. Monoamine Oxidase Inhibitors: A Modern Guide to an Unrequited Class of Antidepressants , 2008, CNS Spectrums.
[48] N. Uysal,et al. Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats. , 2006, Physiological research.
[49] X. Ou,et al. Monoamine oxidases in major depressive disorder and alcoholism. , 2012, Drug discoveries & therapeutics.
[50] Sylvain Houle,et al. Positron Emission Tomography Quantification of [11C]-Harmine Binding to Monoamine Oxidase-A in the Human Brain , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[51] M. Gioulis,et al. Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature , 2013, Neurology and Therapy.
[52] F. Owen,et al. Dopamine is a monoamine oxidase B substrate in man , 1977, Nature.
[53] M. Youdim,et al. Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. , 2010, Current Alzheimer research.
[54] R. Duman. Synaptic plasticity and mood disorders , 2002, Molecular Psychiatry.
[55] P. Riederer,et al. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression , 2016, Journal of Neural Transmission.
[56] P. Tyrer,et al. Monoamine oxidase inhibitors in anxiety disorders. , 1988, Journal of psychiatric research.
[57] G. Wegener,et al. Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. , 2012, Toxicology and applied pharmacology.
[58] P. Riederer,et al. Hydrogen peroxide enhances the activity of monoamine oxidase type-B but not of type-A: a pilot study. , 1986, Journal of neural transmission. Supplementum.
[59] Michael Shannon,et al. The serotonin syndrome. , 2005, The New England journal of medicine.
[60] D. Edmondson. Hydrogen peroxide produced by mitochondrial monoamine oxidase catalysis: biological implications. , 2014, Current pharmaceutical design.
[61] X. Ou,et al. Glucocorticoid and Androgen Activation of Monoamine Oxidase A Is Regulated Differently by R1 and Sp1* , 2006, Journal of Biological Chemistry.
[62] K. Merikangas,et al. Combination monoamine oxidase inhibitor and β-blocker treatment of migraine, with anxiety and depression , 1995, Biological Psychiatry.
[63] L. Reichardt,et al. Neurotrophin-regulated signalling pathways , 2006, Philosophical Transactions of the Royal Society B: Biological Sciences.
[64] Sylvain Houle,et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. , 2006, Archives of general psychiatry.
[65] A. Gjedde,et al. Parkinson's disease and mitochondrial gene variations: A review , 2014, Journal of the Neurological Sciences.
[66] Reinhard Heun,et al. Depression in Alzheimer’s disease: is there a temporal relationship between the onset of depression and the onset of dementia? , 2002, European Psychiatry.
[67] J. P. Petzer,et al. Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. , 2010, Bioorganic & medicinal chemistry.
[68] Keith F. Tipton,et al. The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.
[69] J. E. Villafranca,et al. Inhibition of the Mitochondrial Enzyme ABAD Restores the Amyloid-β-Mediated Deregulation of Estradiol , 2011, PloS one.
[70] M. Maes,et al. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression , 2012, Neuroscience & Biobehavioral Reviews.
[71] M. Berk,et al. eview athways underlying neuroprogression in bipolar disorder : Focus on nflammation , oxidative stress and neurotrophic factors , 2010 .
[72] Irene Bolea,et al. Propargylamine-derived multitarget-directed ligands: fighting Alzheimer’s disease with monoamine oxidase inhibitors , 2013, Journal of Neural Transmission.
[73] P. Riederer,et al. Monoamine oxidase-B inhibition in Alzheimer's disease. , 2004, Neurotoxicology.
[74] R. Duman. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression , 2009, Dialogues in clinical neuroscience.
[75] M. Trivedi,et al. Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression , 1999, Neuropsychopharmacology.
[76] K. Nunn,et al. Epistatic interaction between the monoamine oxidase A and serotonin transporter genes in anorexia nervosa , 2005, European Journal of Human Genetics.
[77] E. Hirsch,et al. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? , 1996, Neurology.
[78] H. Manji,et al. Cellular Plasticity Cascades: Genes-To-Behavior Pathways in Animal Models of Bipolar Disorder , 2006, Biological Psychiatry.
[79] N. Kato,et al. Mitochondrial dysfunction in bipolar disorder. , 2000, Bipolar disorders.
[80] S. Mandel,et al. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives , 2005, Brain Research Reviews.
[81] S. Ross,et al. Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors. , 1986, Biochemical pharmacology.
[82] Ana Cristina Andreazza,et al. The role of neurotrophins in bipolar disorder , 2015, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[83] M. Youdim,et al. Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[84] Vedrana Filić,et al. Monoamine oxidases A and B gene polymorphisms in migraine patients , 2005, Journal of the Neurological Sciences.
[85] A. Mattevi,et al. Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease. , 2014, Biochimica et biophysica acta.
[86] A. Urbani,et al. NMDARs Mediate the Role of Monoamine Oxidase A in Pathological Aggression , 2012, The Journal of Neuroscience.
[87] J. Shih,et al. Monoamine oxidase inactivation: from pathophysiology to therapeutics. , 2008, Advanced drug delivery reviews.
[88] K. Swartz,et al. The Role of Monoamine Oxidase Inhibitors in Current Psychiatric Practice , 2004, Journal of psychiatric practice.
[89] L. Oreland,et al. Associations of MAOA-VNTR or 5HTT-LPR alleles with attention-deficit hyperactivity disorder symptoms are moderated by platelet monoamine oxidase B activity , 2012, Psychiatric genetics.
[90] M. Youdim,et al. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. , 2004, Journal of medicinal chemistry.
[91] U. Bonnet. Moclobemide: therapeutic use and clinical studies. , 2003, CNS drug reviews.
[92] A. Mattevi,et al. Structural properties of human monoamine oxidases A and B. , 2011, International review of neurobiology.
[93] Oliver Wirths,et al. Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease , 2014, Acta Neuropathologica.
[94] T. Nag,et al. Activity-dependent synaptic plasticity modulates the critical phase of brain development , 2016, Brain and Development.
[95] Karmen K. Yoder,et al. Striatal dopamine transporter availability in unmedicated bipolar disorder. , 2011, Bipolar disorders.
[96] Y. Will,et al. Current Concepts in Drug‐Induced Mitochondrial Toxicity , 2009, Current protocols in toxicology.
[97] A. Andreazza,et al. Current State of Biomarkers in Bipolar Disorder , 2014, Current Psychiatry Reports.
[98] Maria Laura Bolognesi,et al. Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer’s disease , 2011, Neurotherapeutics.
[99] K. Kuča,et al. Design, Synthesis and in vitro Evaluation of Indolotacrine Analogues as Multitarget‐Directed Ligands for the Treatment of Alzheimer's Disease , 2016, ChemMedChem.
[100] Tadafumi Kato,et al. Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. , 2008, Cell calcium.
[101] C. Perry,et al. Rasagiline , 2012, Drugs.
[102] Li Wang,et al. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. , 2014, European journal of medicinal chemistry.
[103] Jie-shi Zhang,et al. Study of a possible role of the monoamine oxidase A (MAOA) gene in paranoid schizophrenia among a Chinese population , 2012, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[104] J. Finberg. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. , 2014, Pharmacology & therapeutics.
[105] P. Renshaw,et al. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research , 2005, Molecular Psychiatry.
[106] R. Belmaker,et al. Major depressive disorder. , 2008, The New England journal of medicine.
[107] A. Cavalli,et al. Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer's Disease , 2013, PloS one.
[108] Wei Huang,et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. , 2002, Journal of medicinal chemistry.
[109] S. Ross,et al. Selective monoamine oxidase inhibitors. 4. 4-Aminophenethylamine derivatives with neuron-selective action. , 1986, Journal of medicinal chemistry.
[110] S. Ross,et al. Selective inhibition of monoamine oxidase by p-aminosubstituted phenylalkylamines in catecholaminergic neurones , 1986, Neuropharmacology.
[111] E. Masliah,et al. Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant , 2002, Neuroscience Letters.
[112] Gerta Rücker,et al. Efficacy and Acceptability of Pharmacological Treatments for Depressive Disorders in Primary Care: Systematic Review and Network Meta-Analysis , 2015, The Annals of Family Medicine.
[113] Y. Qian,et al. Linkage studies between attention-deficit hyperactivity disorder and the monoamine oxidase genes. , 2001, American journal of medical genetics.
[114] P. Seeburg,et al. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[115] Lisa Goehler,et al. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. , 2011, Neuro endocrinology letters.
[116] S. Choi,et al. R1, a Novel Repressor of the Human Monoamine Oxidase A* , 2005, Journal of Biological Chemistry.
[117] V. Zurawski,et al. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging , 2015, Neurobiology of Aging.
[118] R. Duman,et al. Chronic Antidepressant Administration Increases the Expression of Camp-specific Phosphodiesterase 4a and 4b Isoforms , 1998 .
[119] Z. Fišar. Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[120] R. Duvoisin,et al. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.
[121] J. Schildkraut,et al. The catecholamine hypothesis of affective disorders. A review of supporting evidence. , 1967, International journal of psychiatry.
[122] M. Carrillo,et al. Why (−)deprenyl prolongs survivals of experimental animals: Increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects , 2002, Mechanisms of Ageing and Development.
[123] L. Olson,et al. Mitochondrial and Ubiquitin Proteasome System Dysfunction in Ageing and Disease: Two Sides of the Same Coin? , 2015, International journal of molecular sciences.
[124] P. Trebon,et al. Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline , 2005, Psychopharmacology.
[125] Y. Oh,et al. Promise of Neurorestoration and Mitochondrial Biogenesis in Parkinson's Disease with Multi Target Drugs: An Alternative to Stem Cell Therapy , 2013, Experimental neurobiology.
[126] Z. Cai. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review). , 2014, Molecular medicine reports.
[127] P. Pacher,et al. The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.
[128] Xi Chen,et al. An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease , 1997, Nature.
[129] P. Malherbe,et al. Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry , 1996, Neuroscience.
[130] Alan A. Wilson,et al. Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[131] S. Hyman,et al. Neural mechanisms of addiction: the role of reward-related learning and memory. , 2006, Annual review of neuroscience.
[132] L. Siever. Neurobiology of aggression and violence. , 2008, The American journal of psychiatry.
[133] T. Mohandas,et al. Human monoamine oxidase A and B genes map to Xp 11.23 and are deleted in a patient with Norrie disease. , 1989, Genomics.
[134] A. Coppen. The Biochemistry of Affective Disorders , 1967, British Journal of Psychiatry.
[135] L. Siever,et al. The neurobiology of aggression and violence , 2015, CNS Spectrums.
[136] M. Youdim,et al. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. , 2000, Journal of neural transmission. Supplementum.
[137] Y. Kumar,et al. Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-aminoethyl)-2,3-dihydroindoles. , 1986, Journal of medicinal chemistry.
[138] J. Shih,et al. Monoamine oxidase: from genes to behavior. , 1999, Annual review of neuroscience.
[139] D. Swaab,et al. A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer's disease patients , 2007, Brain Research.
[140] A. Mattevi,et al. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. , 2009, Biochemistry.
[141] E. Nestler,et al. A molecular and cellular theory of depression. , 1997, Archives of general psychiatry.
[142] S. Mandel,et al. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.
[143] R. Ramsay,et al. 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. , 2010, Bioorganic & medicinal chemistry.
[144] C. Counsell,et al. Monoamine oxidase B inhibitors for early Parkinson's disease. , 2005, The Cochrane database of systematic reviews.
[145] Z. Fišar,et al. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. , 2010, Neuro endocrinology letters.
[146] G. Nowak,et al. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors , 2012, Inflammopharmacology.
[147] H. Manji,et al. Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway. , 2007, CNS & neurological disorders drug targets.
[148] D. Charney,et al. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. , 1996, Pharmacopsychiatry.
[149] Hyoung-Gon Lee,et al. Neuronal failure in Alzheimer’s disease: a view through the oxidative stress looking-glass , 2014, Neuroscience Bulletin.
[150] J. Shih,et al. Transcriptional regulation and multiple functions of MAO genes , 2011, Journal of Neural Transmission.
[151] M. Youdim. Rasagiline: an anti-Parkinson drug with neuroprotective activity , 2003, Expert review of neurotherapeutics.
[152] M. Youdim,et al. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β‐amyloid in ageing and Alzheimer's disease , 2016, British journal of pharmacology.
[153] R. Ramsay,et al. An improved approach to steady-state analysis of monoamine oxidases , 2011, Journal of Neural Transmission.
[154] M. Youdim,et al. The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection. , 2006, Antioxidants & redox signaling.
[155] Song-Yu Yang,et al. Roles of 17β-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders , 2014, The Journal of Steroid Biochemistry and Molecular Biology.
[156] D. Lahiri,et al. Metal and inflammatory targets for Alzheimer's disease. , 2004, Current drug targets.
[157] D. Lynam,et al. Monoamine oxidase A (MAOA) genotype predicts greater aggression through impulsive reactivity to negative affect , 2015, Behavioural Brain Research.
[158] Xingshu Li,et al. A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease. , 2013, European journal of medicinal chemistry.
[159] A. Duong,et al. Biomarkers for bipolar disorder: current insights , 2015 .
[160] M. Youdim,et al. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson’s disease and other neurodegenerative diseases , 2004, Journal of Neural Transmission.
[161] T. Patil,et al. Zonisamide: A review of the clinical and experimental evidence for its use in Parkinson's disease , 2013, Indian journal of pharmacology.
[162] Roy W Jones,et al. Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer’s disease , 2012, Expert review of neurotherapeutics.
[163] D. Mousseau,et al. An update on amine oxidase inhibitors: Multifaceted drugs , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[164] R. Ramsay,et al. Monoamine oxidases: to inhibit or not to inhibit. , 2003, Mini reviews in medicinal chemistry.
[165] A. Goodman. Neurobiology of addiction. An integrative review. , 2008, Biochemical pharmacology.
[166] A. Caspi,et al. Role of Genotype in the Cycle of Violence in Maltreated Children , 2002, Science.
[167] M. Mesulam. Neuroplasticity Failure in Alzheimer's Disease Bridging the Gap between Plaques and Tangles , 1999, Neuron.
[168] S. Henriot,et al. Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings. , 1994, Journal of neural transmission. Supplementum.
[169] P. Lazarovici,et al. Neuroprotective Effects of Novel Cholinesterase Inhibitors Derived from Rasagiline as Potential Anti‐Alzheimer Drugs , 2001, Annals of the New York Academy of Sciences.
[170] W. Drevets,et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. , 2006, Archives of general psychiatry.
[171] Sheridan M. Hoy,et al. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. , 2012, Drugs.
[172] M. Youdim,et al. Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil , 2007, Annals of the New York Academy of Sciences.
[173] K. Kuča,et al. In vitro effects of acetylcholinesterase reactivators on monoamine oxidase activity. , 2011, Toxicology letters.
[174] C. Pittenger,et al. Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms , 2008, Neuropsychopharmacology.
[175] K. Shulman,et al. Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression , 2013, CNS Drugs.
[176] M. Austin,et al. Mechanistic Role for a Novel Glucocorticoid-KLF11 (TIEG2) Protein Pathway in Stress-induced Monoamine Oxidase A Expression* , 2012, The Journal of Biological Chemistry.
[177] P. Benfield,et al. Moclobemide. An update of its pharmacological properties and therapeutic use. , 1996 .
[178] Ying Yang,et al. Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. , 2010, Bioorganic & medicinal chemistry.
[179] Peter V Coveney,et al. Monotopic enzymes and lipid bilayers: a comparative study. , 2007, Biochemistry.
[180] Subrata K. Bose,et al. Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB , 2011, Psychopharmacology.
[181] S. Esteban,et al. Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.
[182] C. Pérez,et al. Multipotent, permeable drug ASS234 inhibits Aβ aggregation, possesses antioxidant properties and protects from Aβ-induced apoptosis in vitro. , 2013, Current Alzheimer research.
[183] Z. Fišar. Inhibition of monoamine oxidase activity by cannabinoids , 2010, Naunyn-Schmiedeberg's Archives of Pharmacology.
[184] Ana Martínez,et al. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease , 2006, Expert opinion on investigational drugs.
[185] P. Gillman,et al. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[186] K. Tipton,et al. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. , 1988, Journal of neural transmission. Supplementum.
[187] Ronald S Duman,et al. NEUROBIOLOGY OF STRESS, DEPRESSION, AND RAPID ACTING ANTIDEPRESSANTS: REMODELING SYNAPTIC CONNECTIONS , 2014, Depression and anxiety.
[188] M. Youdim,et al. Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. , 2010, Current Alzheimer research.
[189] J. Meyer,et al. Neuroimaging Markers of Cellular Function in Major Depressive Disorder: Implications for Therapeutics, Personalized Medicine, and Prevention , 2012, Clinical pharmacology and therapeutics.
[190] G. Chouinard,et al. Moclobemide Update of its Pharmacological Properties and Therapeutic Use , 1996 .
[191] M. Nelen,et al. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. , 1993, Science.
[192] Alan A. Wilson,et al. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. , 2009, Archives of general psychiatry.
[193] M. Naoi,et al. Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase , 2004, InflammoPharmacology.
[194] T. Hergueta,et al. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. , 1990, British journal of clinical pharmacology.
[195] Carlos A. Zarate,et al. Cellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder , 2006, Biological Psychiatry.
[196] V. Chekhonin,et al. Genetic determinants of aggression and impulsivity in humans , 2012, Journal of Applied Genetics.
[197] Z. Fišar,et al. Intracellular signalling pathways and mood disorders. , 2010, Folia biologica.
[198] G. Demaagd,et al. Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options. , 2015, P & T : a peer-reviewed journal for formulary management.
[199] J. Mann,et al. An Association between a Functional Polymorphism in the Monoamine Oxidase A Gene Promoter, Impulsive Traits and Early Abuse Experiences , 2004, Neuropsychopharmacology.
[200] N. Craddock,et al. Association studies of bipolar disorder. , 2001, Bipolar disorders.
[201] J. Jankovic,et al. Variability and validity of polymorphism association studies in Parkinson’s disease , 2000, Neurology.
[202] D. Rujescu,et al. Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[203] A. Holt,et al. On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. , 2004, Neurotoxicology.
[204] P. Söderkvist,et al. G/A polymorphism in intronic sequence affects the processing of MAO‐B gene in patients with Parkinson disease , 2012, FEBS letters.
[205] S. Channon,et al. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. , 1995, Journal of clinical psychopharmacology.
[206] R. Duman,et al. A Neurotrophic Model for Stress-Related Mood Disorders , 2006, Biological Psychiatry.
[207] J. Krystal,et al. MAOA Genotype, Maltreatment, and Aggressive Behavior: The Changing Impact of Genotype at Varying Levels of Trauma , 2009, Biological Psychiatry.
[208] Namrata Singh,et al. Mitochondrial Dysfunctions in Neurodegenerative Diseases: Relevance to Alzheimer's Disease , 2014, BioMed research international.
[209] L. Oreland,et al. Platelet MAO and personality--function and dysfunction. , 2004, Current medicinal chemistry.
[210] J. Thome,et al. cAMP Response Element-Mediated Gene Transcription Is Upregulated by Chronic Antidepressant Treatment , 2000, The Journal of Neuroscience.
[211] Wenhua Liu,et al. Parkin Suppresses the Expression of Monoamine Oxidases* , 2006, Journal of Biological Chemistry.
[212] G. Fazio,et al. Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders , 2010 .
[213] S. Yan,et al. Identification of human ABAD inhibitors for rescuing Aβ-mediated mitochondrial dysfunction. , 2014, Current Alzheimer research.
[214] J. Schildkraut,et al. Platelet monoamine oxidase activity and deficit syndrome schizophrenia , 1995, Psychiatry Research.
[215] R. Nelson,et al. Nitric oxide and serotonin interactions in aggression. , 2014, Current topics in behavioral neurosciences.
[216] P. Riederer,et al. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson’s disease , 2004, Neurology.
[217] M. Mattson,et al. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. , 2010, Antioxidants & redox signaling.
[218] M. Radicioni,et al. Pressor Response to Oral Tyramine and Monoamine Oxidase Inhibition During Treatment with Ralfinamide (NW-1029) , 2012, Neurotoxicity Research.
[219] H. Hampel,et al. Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics , 2011, Journal of Neural Transmission.
[220] M. Maj,et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression , 2009, Metabolic Brain Disease.
[221] Christophe Mulle,et al. Activity‐dependent synaptic plasticity of NMDA receptors , 2010, The Journal of physiology.